Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06173531 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06173531 · ClinicalTrials.gov record · last posted 2025-09-10

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

StatusActive, Not Recruiting
PhasePhase 3
Started2023-11-27
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 10, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)

Amendment record 21 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 21 times since 2023-12-08; most recent amendment 2025-09-03. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-06-12
Status change Recruiting→Active, Not Recruitingv17
2024-01-23
Status change Enrolling by Invitation→Recruitingv2
Trial Details
NCT Number NCT06173531
Lead Sponsor ACADIA Pharmaceuticals Inc.
Conditions Hyperphagia in Prader-Willi Syndrome
Enrollment 170 participants
Start Date 2023-11-27
Primary Completion 2025-10 (estimated)
Study Completion 2025-11 (estimated)
Updated on ClinicalTrials.gov 2025-09-10